Acadia reiterated at market outperform by JMP

Acadia Pharmaceuticals Inc. was reiterated at market outperform with an $18 price target by JMP Securities analyst Charles C. Duncan. An expert Parkinson's disease (PD) doctor affirmed optimism of the company's ACP-103; via a conference call. The expert specifically supported JMP's thesis that the safety and efficacy profile observed in the phase 2 trial of ACP-103 for treatment-induced psychosis in PD is indicative of success in pivotal trials. Shares of the San Diego pharmaceutical company were unchanged at $15.70 on volume of 593,825 shares versus the three-month running average of 614,647 shares. (Nasdaq: LLY)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.